JP2022542670A5 - - Google Patents
Info
- Publication number
- JP2022542670A5 JP2022542670A5 JP2022504629A JP2022504629A JP2022542670A5 JP 2022542670 A5 JP2022542670 A5 JP 2022542670A5 JP 2022504629 A JP2022504629 A JP 2022504629A JP 2022504629 A JP2022504629 A JP 2022504629A JP 2022542670 A5 JP2022542670 A5 JP 2022542670A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- amino acid
- seq
- acid sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025145010A JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878977P | 2019-07-26 | 2019-07-26 | |
| US62/878,977 | 2019-07-26 | ||
| PCT/KR2020/009870 WO2021020845A1 (en) | 2019-07-26 | 2020-07-27 | Anti-egfr/anti-4-1bb bispecific antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145010A Division JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542670A JP2022542670A (ja) | 2022-10-06 |
| JP2022542670A5 true JP2022542670A5 (enExample) | 2023-08-03 |
| JP7738545B2 JP7738545B2 (ja) | 2025-09-12 |
Family
ID=74189704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504629A Active JP7738545B2 (ja) | 2019-07-26 | 2020-07-27 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
| JP2025145010A Pending JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145010A Pending JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12168690B2 (enExample) |
| EP (1) | EP4004053A4 (enExample) |
| JP (2) | JP7738545B2 (enExample) |
| KR (1) | KR20220038767A (enExample) |
| CN (2) | CN118221825A (enExample) |
| AU (1) | AU2020320349A1 (enExample) |
| BR (1) | BR112022001329A2 (enExample) |
| CA (1) | CA3147420A1 (enExample) |
| MX (1) | MX2022001027A (enExample) |
| WO (1) | WO2021020845A1 (enExample) |
| ZA (1) | ZA202200905B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11261259B2 (en) | 2019-08-12 | 2022-03-01 | I-Mab Biopharma Us Limited | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof |
| WO2022072087A1 (en) * | 2020-10-01 | 2022-04-07 | QC Ware Corp. | Quantum number preserving circuits for preparing quantum states representing fermions in computational units-based quantum computers |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| CN118369340A (zh) * | 2021-11-25 | 2024-07-19 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗原结合蛋白 |
| EP4504790A4 (en) * | 2022-04-07 | 2026-04-08 | Yuhan Corp | Pharmaceutical composition for treating or preventing cancer with low HER2 expression |
| WO2024143643A1 (ko) * | 2022-12-30 | 2024-07-04 | 앱클론(주) | Cd137에 특이적으로 결합하는 어피바디 및 이의 용도 |
| KR20240164748A (ko) * | 2023-05-12 | 2024-11-20 | 앱클론(주) | 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체 |
| KR102927129B1 (ko) | 2025-03-18 | 2026-02-11 | 이트너스 주식회사 | 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69624436T2 (de) | 1995-04-08 | 2003-08-28 | Lg Chemical Ltd., Seoul/Soul | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| BRPI0607315B1 (pt) | 2005-02-07 | 2022-05-17 | Roche Glycart Ag | Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra |
| WO2008028686A2 (en) * | 2006-09-10 | 2008-03-13 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| KR102319582B1 (ko) * | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| SG11201808196UA (en) | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| BR112018071612A2 (pt) * | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| JP7160833B2 (ja) * | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| US11725060B2 (en) | 2017-07-20 | 2023-08-15 | Aptevo Reserch and Development LLC | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods |
| JP2021508478A (ja) * | 2017-12-28 | 2021-03-11 | ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ | ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ） |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| SG11202105152YA (en) * | 2018-11-30 | 2021-06-29 | Abl Bio Inc | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| US11261259B2 (en) * | 2019-08-12 | 2022-03-01 | I-Mab Biopharma Us Limited | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof |
| CN115190889A (zh) * | 2020-02-28 | 2022-10-14 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体、多特异性抗体及其用途 |
-
2020
- 2020-07-27 MX MX2022001027A patent/MX2022001027A/es unknown
- 2020-07-27 WO PCT/KR2020/009870 patent/WO2021020845A1/en not_active Ceased
- 2020-07-27 AU AU2020320349A patent/AU2020320349A1/en active Pending
- 2020-07-27 CA CA3147420A patent/CA3147420A1/en active Pending
- 2020-07-27 CN CN202410360186.5A patent/CN118221825A/zh active Pending
- 2020-07-27 CN CN202080053851.6A patent/CN114450306B/zh active Active
- 2020-07-27 KR KR1020227006641A patent/KR20220038767A/ko active Pending
- 2020-07-27 JP JP2022504629A patent/JP7738545B2/ja active Active
- 2020-07-27 EP EP20848658.9A patent/EP4004053A4/en active Pending
- 2020-07-27 US US16/939,472 patent/US12168690B2/en active Active
- 2020-07-27 BR BR112022001329A patent/BR112022001329A2/pt unknown
-
2022
- 2022-01-19 ZA ZA2022/00905A patent/ZA202200905B/en unknown
-
2024
- 2024-11-04 US US18/935,875 patent/US20250066487A1/en active Pending
-
2025
- 2025-09-02 JP JP2025145010A patent/JP2026004296A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542574A5 (enExample) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2021531254A5 (enExample) | ||
| JP2022079549A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2023548443A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| JP2022540083A5 (enExample) | ||
| JP2022530404A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2006020633A (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| JP2022546454A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2024056817A5 (enExample) | ||
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| JP2018514193A5 (enExample) | ||
| JP2026004299A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2022513043A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2017507131A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JP2021511387A5 (enExample) | ||
| JP2021518415A5 (enExample) |